BioNTech evokes a return to normal in a year

The general manager of the German company BioNTech, which has developed a vaccine against the new coronavirus with Pfizer, spoke on Sunday of a possible return to normal by next winter.

• Read also: Confidence in vaccines crucial to stop COVID-19

• Read also: COVID-19 vaccine: a “breakthrough” from which everyone must quickly benefit

• Read also: Ottawa reserves 56 million more doses of Pfizer vaccine

On the BBC, Professor Ugur Sahin considered it “absolutely essential” to have a high vaccination rate before the fall of 2021.

“If everything continues to go well, we will start delivering the vaccine at the end of this year,” he said. “Our goal is to deliver more than 300 million doses of vaccine until April next year, which would allow us to start making an impact” against the virus, which has killed more than 1.3 million in the world.

“The biggest impact will take place until the summer. Summer will help us anyway because the infection rate will drop, ”he continued. “What is absolutely essential is that we have a significant vaccination rate before fall / winter next year.”

“I’m confident that will happen” because many vaccine manufacturers have been asked to increase production, he said, adding, “We could have a normal winter next year.”

According to Pfizer and BioNTech, their vaccine is “90% effective” against COVID-19, according to the large-scale phase 3 trial still underway, the last step before an application for approval. Several other vaccines are also at this stage of research, suggesting the horizon of a return to normal.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.